文章摘要
张 盛,李少儒.卵巢浆液性肿瘤组织中的HOXA9蛋白的表达及其对卵巢癌预后的影响[J].南京医科大学学报,2018,(7):988~993
卵巢浆液性肿瘤组织中的HOXA9蛋白的表达及其对卵巢癌预后的影响
Expression of HOXA9 protein in ovarian serous tumors and its potential as a specific marker for early diagnosis and drug resistance in ovarian cancer
投稿时间:2017-08-25  
DOI:10.7655/NYDXBNS20180722
中文关键词: 浆液性  卵巢癌  HOXA9蛋白  免疫组化  预后  生存分析
英文关键词: microRNA  islet β⁃cell  proliferation inhibition
基金项目:
作者单位
张 盛 宁夏回族自治区工人医院普外科宁夏 银川 750000 
李少儒 新乡医学院第一附属医院妇产科河南 新乡 453100) 
摘要点击次数: 1054
全文下载次数: 915
中文摘要:
      目的:探讨浆液性卵巢癌高HOXA9表达的临床病理意义。方法:对178例浆液性卵巢癌患者、72例卵巢交界性肿瘤患者和69例良性卵巢肿瘤患者进行HOXA9免疫组织化学染色。HOXA9高表达与卵巢癌临床病理特征的关系采用χ2检验和Fisher精确检验。采用Kaplan?Meier法计算总生存(OS)率,用Cox比例风险模型分析预后因素与患者生存期的关系。结果:浆液性卵巢癌中HOXA9蛋白表达阳性率(75.8%,135/178)明显高于良性浆液性肿瘤(34.8%,24/69,P < 0.05)。同样,浆液性卵巢癌中HOXA9蛋白强阳性表达率(59.6%,106/178)明显高于良性浆液性肿瘤(11.6%,8/69,P < 0.05)。高级别(65.1%,71/109)卵巢癌中强阳性HOXA9蛋白表达率显著高于低级别病例(47.8%,33/69,P=0.014),同样转移卵巢癌中HOXA9蛋白强阳性表达率(72.6%,69/95)显著高于无转移卵巢癌(42.2%,35/83,P < 0.001)。关于FIGO临床分期,晚期(ⅡB~ⅢC)卵巢癌中强阳性HOXA9表达率为69.1%(65/94),而在早期(I~IIA期)病例中仅为46.4%(39/84),两者比较差异有统计学意义(P=0.003)。HOXA9强表达患者的OS率低于HOXA9弱表达患者(Log?rank=43.765,P < 0.001)。多因素分析显示,HOXA9是卵巢癌患者的独立预后因子。结论:HOXA9的表达与卵巢癌的分级和转归密切相关,可作为临床治疗有用的特异性标志物。
英文摘要:
      Objective:To investigate the expression of HOXA9 protein in ovarian serous tumors and its potential as a specific marker for early diagnosis and drug resistance in ovarian cancer. Methods:Immunohistochemical staining for HOXA9 was performed in 178 patients with serous ovarian carcinoma,in 72 patients with ovarian borderline tumors and in 69 patients with benign ovarian tumors. The correlations between high HOXA9 expression and the clinicopathological features of the ovarian carcinomas were evaluated by the χ2 test and Fisher's exact test. The overall survival(OS)rates were calculated by the Kaplan?Meier method,and the association between prognostic factors and patient survival was analyzed by the Cox proportional hazard model. Results:The positive rate of HOXA9 protein in serous ovarian cancer(75.8%,135/178)was significantly higher than that in benign serous tumors(34.8%,24/69)(P < 0.05). Similarly,the strong positive expression rate of HOXA9 protein in serous ovarian cancer(59.6%,106/178)was significantly higher than that in benign serous tumors(11.6%,8/69)(P < 0.05). The positive expression rate of HOXA9 in high grade(65.1%,71/109)ovarian cancer was significantly higher than that in lower grade(47.8%,33/69)(P=0.014). Similarly,the positive expression rate of HOXA9 in metastatic ovarian cancer(72.6%,69/95)was significantly higher than that in ovarian cancer without metastasis(42.2%,35/83)(P < 0.001). Regarding the FIGO clinical stage,strong positive HOXA9 expression was 69.1%(65/94)in advanced(ⅡB?ⅢC)ovarian cancers and only 46.4%(39/84)in early(stageⅠ?ⅡA)ovarian cancers. The difference was statistically significant(P=0.003). The OS rate of patients with strong expression of HOXA9 was lower than that of patients with weak expression of HOXA9(Log?rank=43.765,P < 0.001). Multivariate analysis showed that HOXA9 was an independent prognostic factor in patients with ovarian cancer. Conclusion:HOXA9 expression is strongly associated with grade and outcome in ovarian carcinoma,and may serve as a useful molecular marker for clinical management.
查看全文   查看/发表评论  下载PDF阅读器